SCHEMBL6862874

SCHEMBL6862874

CCOc1cc(CO)cc2[nH]ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 3/20 0.48
HTT P42858 1/20 0.36
S1PR1 P21453 4/20 0.36
S1PR3 Q99500 3/20 0.36
DHFR P00374 1/20 0.36
HTR1A P08908 4/20 0.35
LMNA P02545 3/20 0.34
HTR1B P28222 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
ADRB2 P07550 2/20 0.34
ADRB1 P08588 2/20 0.34
ADRB3 P13945 2/20 0.34
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
CYP2D6 P10635 1/20 0.34
THRB P10828 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16452871 0.85 RHEB (0.46) RHEBHTR1ALMNAHTR1BCYP1A2
SCHEMBL6872834 0.81 RHEB (0.48) RHEBDRD4DRD3ALDH1A1
SCHEMBL19329763 0.79 KDM4E (0.45) RHEBS1PR1S1PR3DHFRHTR1B
SCHEMBL11450500 0.77 HTR1A (0.47) RHEBHTR1ALMNAHTR1BCYP1A2
SCHEMBL11451085 0.77 RHEB (0.42) RHEBLMNACYP1A2CYP3A4TSHR
SCHEMBL11459555 0.76 HTR1A (0.55) HTTHTR1ALMNAHTR1BCYP1A2
SCHEMBL11460034 0.76 ADRB2 (0.67) HTR1ALMNAHTR1BCYP1A2CYP3A4
SCHEMBL25080566 0.75 RHEB (0.50) RHEBKDM4EGLAALOX15ALDH1A1
SCHEMBL11457356 0.75 ADRB2 (0.48) HTR1ALMNAHTR1BCYP1A2CYP3A4
SCHEMBL2957852 0.74 ALDH1A1 (0.49) S1PR1S1PR3DHFRLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280796-B1 PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2004-03-24 EP disclosed
US-6703397-B2 REACTING A NITRILE GROUP CONTAINING INDOLE DERIVEATIVE WITH GUANIDINE OR SALT; USEFUL AS PROHYLAXIS OR THERAPEUTICAL TREATMENT OF INFECTIOUS DISEASES BASILEA PHARMACEUTICA AG (CH) 2004-03-09 US disclosed
US-20030119857-A1 Pyrimidinyl methyl indole derivatives with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2003-06-26 US disclosed
EP-1280796-A1 PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY Basilea Pharmaceutica AG (CH) 2003-02-05 EP disclosed
WO-2001083474-A1 PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119857-A1 Pyrimidinyl methyl indole derivatives with antibacterial activity IDO1, IDO2, AANAT RHEB 3680/4885HTT 2407/4885S1PR1 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.